The role of the nonsurgical oncologist in the management of advanced transitional cell cancer. Part II: metastatic disease
The role of the nonsurgical oncologist in the management of advanced transitional cell cancer. Part II: metastatic disease
TCC may arise at any site in the urinary tract, and when advanced or metastatic can be regarded by the nonsurgical oncologist as a single tumour type. TCCs commonly develop histologically and may be admixed with areas of squamous carcinoma, adenocarcinoma or peripheral neuro-ectodermal tumour. In most cases this does not alter the therapeutic approach, although it might alter the outcome.
TCCs arise most commonly in the bladder, where they are the fourth most common cancer in men and eighth most common in women, responsible for >5000 deaths annually in the UK. They occur increasingly commonly with age, and advanced disease in the elderly is a common clinical management problem, which necessitates adjustment to treatment regimens.
Locally advanced disease is routinely managed by cystectomy, with the possibility of bladder reconstruction for selected patients. However, more recently there has been renewed interest in bladder-sparing approaches, including radiotherapy and chemo/radiotherapy. Neoadjuvant chemotherapy has been evaluated in large randomized trials and similar international studies are ongoing, testing the usefulness of adjuvant chemotherapy after chemotherapy. These nonsurgical approaches to this group of cancers will be considered in this review, with an emphasis on data obtained from prospective randomized trials.
981-984
Mead, G.M.
8a97f978-9c66-4a16-bb03-dd83d20b06a0
Roberts, J.T.
a30db871-0972-48ab-b18c-390f134c6915
10 November 2004
Mead, G.M.
8a97f978-9c66-4a16-bb03-dd83d20b06a0
Roberts, J.T.
a30db871-0972-48ab-b18c-390f134c6915
Mead, G.M. and Roberts, J.T.
(2004)
The role of the nonsurgical oncologist in the management of advanced transitional cell cancer. Part II: metastatic disease.
BJU International, 94 (7), .
(doi:10.1111/j.1464-410X.2004.05090.x).
Abstract
TCC may arise at any site in the urinary tract, and when advanced or metastatic can be regarded by the nonsurgical oncologist as a single tumour type. TCCs commonly develop histologically and may be admixed with areas of squamous carcinoma, adenocarcinoma or peripheral neuro-ectodermal tumour. In most cases this does not alter the therapeutic approach, although it might alter the outcome.
TCCs arise most commonly in the bladder, where they are the fourth most common cancer in men and eighth most common in women, responsible for >5000 deaths annually in the UK. They occur increasingly commonly with age, and advanced disease in the elderly is a common clinical management problem, which necessitates adjustment to treatment regimens.
Locally advanced disease is routinely managed by cystectomy, with the possibility of bladder reconstruction for selected patients. However, more recently there has been renewed interest in bladder-sparing approaches, including radiotherapy and chemo/radiotherapy. Neoadjuvant chemotherapy has been evaluated in large randomized trials and similar international studies are ongoing, testing the usefulness of adjuvant chemotherapy after chemotherapy. These nonsurgical approaches to this group of cancers will be considered in this review, with an emphasis on data obtained from prospective randomized trials.
This record has no associated files available for download.
More information
Published date: 10 November 2004
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 26475
URI: http://eprints.soton.ac.uk/id/eprint/26475
ISSN: 1464-4096
PURE UUID: 314d8ef0-2e9e-4ad3-9c73-32d7e800889c
Catalogue record
Date deposited: 21 Apr 2006
Last modified: 15 Mar 2024 07:11
Export record
Altmetrics
Contributors
Author:
G.M. Mead
Author:
J.T. Roberts
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics